NO20005836L - Hybride polypeptider med forsterkede farmakokinetiske egenskaper - Google Patents

Hybride polypeptider med forsterkede farmakokinetiske egenskaper

Info

Publication number
NO20005836L
NO20005836L NO20005836A NO20005836A NO20005836L NO 20005836 L NO20005836 L NO 20005836L NO 20005836 A NO20005836 A NO 20005836A NO 20005836 A NO20005836 A NO 20005836A NO 20005836 L NO20005836 L NO 20005836L
Authority
NO
Norway
Prior art keywords
pharmacokinetic properties
hybrid polypeptides
enhanced pharmacokinetic
enhanced
polypeptides
Prior art date
Application number
NO20005836A
Other languages
English (en)
Other versions
NO20005836D0 (no
Inventor
Shawn Barney
Kelly I Guthrie
Gene Merutka
Mohmed Anwer
Dennis M Lambert
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of NO20005836D0 publication Critical patent/NO20005836D0/no
Publication of NO20005836L publication Critical patent/NO20005836L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20005836A 1998-05-20 2000-11-17 Hybride polypeptider med forsterkede farmakokinetiske egenskaper NO20005836L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/082,279 US6258782B1 (en) 1998-05-20 1998-05-20 Hybrid polypeptides with enhanced pharmacokinetic properties
PCT/US1999/011219 WO1999059615A1 (en) 1998-05-20 1999-05-20 Hybrid polypeptides with enhanced pharmacokinetic properties

Publications (2)

Publication Number Publication Date
NO20005836D0 NO20005836D0 (no) 2000-11-17
NO20005836L true NO20005836L (no) 2001-01-19

Family

ID=22170199

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005836A NO20005836L (no) 1998-05-20 2000-11-17 Hybride polypeptider med forsterkede farmakokinetiske egenskaper

Country Status (22)

Country Link
US (3) US6258782B1 (no)
EP (1) EP1079846A4 (no)
JP (1) JP2002515449A (no)
KR (1) KR100742789B1 (no)
CN (1) CN1205995C (no)
AU (1) AU766995C (no)
BR (1) BR9910626A (no)
CA (1) CA2332338A1 (no)
HK (1) HK1039747A1 (no)
HR (1) HRP20000789A2 (no)
HU (1) HUP0101826A3 (no)
ID (1) ID29141A (no)
IL (2) IL139702A0 (no)
MX (1) MXPA00011314A (no)
NO (1) NO20005836L (no)
NZ (1) NZ508352A (no)
PL (1) PL344342A1 (no)
RU (1) RU2236865C2 (no)
TR (1) TR200100163T2 (no)
WO (1) WO1999059615A1 (no)
YU (1) YU71800A (no)
ZA (1) ZA200006642B (no)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723158B2 (en) * 1995-06-07 2000-08-17 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cell
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) * 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US6372494B1 (en) 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
DK1264840T3 (da) * 1999-05-17 2009-11-16 Conjuchem Biotechnologies Inc Langtidsvirkende fusionspeptidinhibitorer af viral infektion
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6277974B1 (en) 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US6623741B1 (en) * 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
US6528308B1 (en) 2000-03-16 2003-03-04 Duke University Suppressor of HIV replication and transcription
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
KR100447943B1 (ko) * 2000-11-06 2004-09-08 한국과학기술연구원 Ｈｉｖ의 감염 억제 펩타이드
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
EP1479691B1 (en) * 2001-05-31 2006-11-15 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors for HIV infection
EP1752469B1 (en) * 2001-05-31 2008-10-29 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors for HIV infection
ES2242860T3 (es) * 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
WO2002098365A2 (en) * 2001-06-07 2002-12-12 Skinmedica, Inc. Conditioned cell culture media and uses thereof
CN1255548C (zh) 2001-06-15 2006-05-10 霍夫曼-拉罗奇有限公司 gp41片段的乙酰化
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
IL160289A0 (en) * 2001-08-30 2004-07-25 Biorexis Pharmaceutical Corp Modified transferrin fusion proteins
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
FR2832715A1 (fr) * 2001-11-29 2003-05-30 Hippocampe Polypeptides inhibiteurs de l'infectivite des virus de l'immunodeficience humaine
WO2003066078A1 (en) * 2002-02-07 2003-08-14 Delta Biotechnology Limited Hiv inhibiting proteins
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
NZ534947A (en) 2002-02-22 2008-03-28 Progenics Pharm Inc Anti-CCR5 antibody that binds to CCR5 on the surface of a human cell.
BR0303362A (pt) * 2002-03-06 2005-07-19 Univ Arizona State Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
WO2004013165A1 (en) * 2002-07-24 2004-02-12 F. Hoffmann-La Roche Ag Pegylated t1249 polypeptide
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
DE60333306D1 (de) * 2002-08-30 2010-08-19 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
CA2500248C (en) * 2002-09-24 2013-03-19 Frontier Biotechnologies Co., Ltd. Peptide derivative fusion inhibitors of hiv infection
US20040076637A1 (en) * 2002-09-27 2004-04-22 Delmedico Mary Kay HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
US7420037B2 (en) * 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
US20060233808A1 (en) * 2003-04-04 2006-10-19 David Deperthes Peptabody for cancer treatment
DE60336978D1 (de) * 2003-04-11 2011-06-16 Pasteur Institut Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US7379700B2 (en) * 2003-05-06 2008-05-27 Canon Kabushiki Kaisha Image reading apparatus with rotatable internal and external guides
WO2004106364A1 (en) * 2003-08-05 2004-12-09 Cornell Research Foundation, Inc. Stabilizing peptides and their use in the preparation of stabilized hiv inhibitors
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
JP2007512001A (ja) * 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Ｅｐｏミメティックペプチドおよび融合タンパク質
CA2548181A1 (en) 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
RU2006128593A (ru) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека
DE602005016658D1 (de) * 2004-04-08 2009-10-29 Jadolabs Gmbh Dreigeteilte konjugate mit einer struktur, die mit zellmembran-rafts interagieren und ihre verwendung
US20080039532A1 (en) * 2004-05-06 2008-02-14 Dominique Bridon Compounds For Specific Viral Target
GB0422439D0 (en) * 2004-10-08 2004-11-10 European Molecular Biology Lab Embl Inhibitors of infection
US20070041943A1 (en) * 2004-12-29 2007-02-22 Children's Hospital Research Expression of virus entry inhibitors and recombinant AAV thereof
JP2009514790A (ja) * 2005-07-22 2009-04-09 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Ｈｉｖ−１−感染患者におけるウイルス負荷を減少させる方法
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
AR059300A1 (es) * 2006-02-02 2008-03-26 Trimeris Inc Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
ATE524493T1 (de) 2006-07-24 2011-09-15 Biorexis Pharmaceutical Corp Exendin-fusionsproteine
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2054086A1 (en) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG A conjugate of an antibody against ccr5 and an antifusogenic peptide
AU2007331195A1 (en) 2006-12-12 2008-06-19 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
US20090143288A1 (en) * 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
MX2009010689A (es) * 2007-04-03 2009-12-14 Trimeris Inc Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
EP2147016A2 (en) * 2007-05-16 2010-01-27 ConjuChem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
WO2010120541A2 (en) * 2009-03-31 2010-10-21 University Of Washington Compositions and methods for modulating the activity of complement regulatory proteins on target cells
EP2413975A1 (en) * 2009-04-01 2012-02-08 Yeda Research and Development Co. Ltd. Lipopeptide inhibitors of hiv-1
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
BR112013002292A2 (pt) 2010-09-14 2016-06-14 Hoffmann La Roche polipeptídeo du fusão, complexo de proteína, uso e kit
US9273092B2 (en) * 2011-12-23 2016-03-01 RioGin LLC Selective binding compounds
CN104136455B (zh) * 2012-02-27 2017-05-17 中国人民解放军军事医学科学院毒物药物研究所 抗hiv‑1多肽及其用途
WO2013150532A1 (en) 2012-04-04 2013-10-10 Yeda Research And Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
US9657064B2 (en) 2012-09-13 2017-05-23 Les Hopitaux Universitaires De Geneve Cell penetrating peptides
EP2968469A4 (en) 2013-03-15 2016-08-31 Longevity Biotech Inc PEPTIDES COMPRISING NON-ENDOGENIC AMINO ACIDS AND METHODS OF MAKING AND USING SAME
CN105646717B (zh) * 2016-01-26 2020-06-09 复旦大学 一种长效hiv融合抑制剂及其应用
EP3214093A1 (en) * 2016-03-03 2017-09-06 Fondation The Ark Fusion respiratory syncytial virus inhibitors and use thereof
CN106279373B (zh) * 2016-08-17 2020-01-24 广州宏柯源生物科技有限公司 一种多肽起泡剂、其制备方法及应用
US20190255165A1 (en) 2016-09-21 2019-08-22 Amal Therapeutics Sa Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer
CA3080076A1 (en) * 2017-08-29 2019-03-07 Pharis Biotec Gmbh Protransduzin-d - improved enhancer of gene transfer
CN110357968B (zh) * 2018-04-08 2023-08-25 吉林省汇融生物科技有限公司 抗肿瘤融合蛋白及其制法和应用
CN116162136A (zh) * 2021-11-24 2023-05-26 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
CN117186187B (zh) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272858A3 (en) * 1986-12-15 1989-07-12 Repligen Corporation Recombinant hiv envelope proteins produced in insect cells
AU626797B2 (en) * 1987-09-08 1992-08-13 Albany Medical College Immunogenic composites capable of selectively inducing antibody production, pharmaceutical compositions employing the same and method of selectively inducing antibody production
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
IE904083A1 (en) * 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
US6248574B1 (en) * 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
ZA934199B (en) * 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
ES2139017T3 (es) 1992-07-20 2000-02-01 Univ Duke Compuestos que inhiben la replicacion del vih.
CA2150371C (en) * 1992-12-11 2002-09-17 Dov Borovsky Materials and methods for control of pests
US5464934A (en) 1993-05-14 1995-11-07 Mallinckrodt Medical, Inc. Metal chelates as spacer compounds in biologically active peptides
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties

Also Published As

Publication number Publication date
JP2002515449A (ja) 2002-05-28
CN1310626A (zh) 2001-08-29
YU71800A (sh) 2004-05-12
ID29141A (id) 2001-08-02
HUP0101826A2 (hu) 2001-09-28
CA2332338A1 (en) 1999-11-25
HUP0101826A3 (en) 2005-12-28
AU766995B2 (en) 2003-10-30
US6562787B1 (en) 2003-05-13
HK1039747A1 (zh) 2002-06-21
BR9910626A (pt) 2006-01-03
EP1079846A4 (en) 2003-01-02
RU2236865C2 (ru) 2004-09-27
US6258782B1 (en) 2001-07-10
WO1999059615A9 (en) 2000-06-22
NO20005836D0 (no) 2000-11-17
WO1999059615A1 (en) 1999-11-25
ZA200006642B (en) 2001-05-28
EP1079846A1 (en) 2001-03-07
US6348568B1 (en) 2002-02-19
IL139702A0 (en) 2002-02-10
KR100742789B1 (ko) 2007-07-25
AU766995C (en) 2004-12-02
IL139702A (en) 2007-10-31
KR20010043681A (ko) 2001-05-25
NZ508352A (en) 2004-02-27
CN1205995C (zh) 2005-06-15
AU4194999A (en) 1999-12-06
MXPA00011314A (es) 2003-04-22
TR200100163T2 (tr) 2001-06-21
PL344342A1 (en) 2001-11-05
HRP20000789A2 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
NO20005836L (no) Hybride polypeptider med forsterkede farmakokinetiske egenskaper
NO20020087D0 (no) Hybride polypeptider med forbedrede farmakokinetiske egenskaper
CY2013019I1 (el) Tροποποιημενα χιμαιρικα πολυπεπτιδια με βελτιωμενες φαρμακοκινητικες ιδιοτητες
NO20002365L (no) Batteripakke
DE50013299D1 (de) Piezoaktor mit verbesserten elektrodenanschlüssen
PL352530A1 (en) Cyclic substituted fused pyrrolocarbazoles and isoindolones
DE69926763D1 (de) Airbag mit umlenkwand
ATE508723T1 (de) Thermoplastische mehrschichtige struktur
NO994730L (no) Vognkarosseri med rammeverk
DE69942126D1 (de) Formkörper
FR2798022B1 (fr) Circuit hybride d'emission-reception
TR199900345A3 (tr) Kusak yapisi gelistirilmis lastik
DE69903134T2 (de) Spritzgiessverfahren und spritzgiessform
FR2791348B1 (fr) POLYPEPTIDE Npt2B
ID27561A (id) Cetakan stempel hibrida
ID26377A (id) Lampu fluoresens berbentuk lampu pijar
DE69829415D1 (de) Formkörper
ATA69399A (de) Verbundkörper
ITMI990624A0 (it) Polipeptidi citotossici
DE59909437D1 (de) Hohlladung
ATA21198A (de) Schalungsanordnung
ITMO990224A0 (it) Attacco conometrico perfezionato
FI3426U1 (fi) Latausjärjestely
SE9802755D0 (sv) Formpressning
HU0105363D0 (en) Cyclic substituted fused pyrrolocarbazoles and isoindolones

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application